Pd05-09 Patients With Upper Tract Urothelial Carcinoma at Minority Serving Hospitals Are Less Likely to Undergo Definitive Treatment

You have accessJournal of UrologyDiversity, Equity non-MSH=27,474). Compared to a non-MSH, patients at a MSH were more likely to be uninsured (4.3 vs 1.2%) and be treated at an academic institution (40.5 vs 34.9%), all p<0.001. Moreover, the average time from diagnosis to definitive treatment was comparable between groups (MSH: 44.6 days, non-MSH: 43.6 days, p=0.685). Rates of definitive treatment were lower at MSHs compared to non-MSHs (84.1 vs 88.2%, p<0.001). On univariate analysis, receiving care at a MSH was a negative predictor of definitive treatment (OR=0.785, p<0.001). On multivariate analysis, treatment at a MSH continued to negatively predict receipt of definitive treatment (OR=0.447, p=0.020) Table 1. Furthermore, increased UTUC surgery volume at the hospital and higher T stage predicted definitive treatment while Medicaid/Medicare or no insurance and lymph node involvement were negative predictors. CONCLUSIONS: Patients with UTUC at a MSH are less likely to undergo definitive treatment. This association is modulated by insurance status and facility volume which suggests that a combination of health access, socioeconomic, and facility-level factors contribute towards racial disparities in UTUC care. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e93 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Christopher S. Connors More articles by this author Micah Levy More articles by this author Daniel Wang More articles by this author Juan Sebastian Arroyave More articles by this author Olamide Omidele More articles by this author Nikit Venishetty More articles by this author Michael Palese More articles by this author Expand All Advertisement PDF downloadLoading ...